217 completed, 98 unknown, 82 active not recruiting, 79 recruiting. 289 Phase 2, 130 Phase 1, 111 Phase 3, 87 Not applicable, 7 Early Phase 1.
Follow Radiotherapy, Intensity-Modulated: new trials by email Literature Review of Radiotherapy, Intensity-Modulated trials Research Report on Radiotherapy, Intensity-Modulated
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma Chemotherapy, Computed Tomography, Endoscopic Procedure - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Not applicable | Not yet recruiting | City of Hope Medical Center | 30 | 2027-06-22 | 2026-11-09 |
| Study to Test Shorter Duration Chemoradiation Therapy Versus Standard Duration Chemoradiation Therapy for Cervical Cancer Biospecimen Collection, Brachytherapy, Cisplatin - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 3 | Not yet recruiting | NRG Oncology | 550 | 2027-05-19 | 2026-11-10 |
| Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection - Grade 1 Meningioma, Grade 2 Meningioma | Phase 3 | Not yet recruiting | NRG Oncology | 464 | 2027-01-28 | 2026-08-25 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-11-18 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT) - Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 3 | Not yet recruiting | Shandong Cancer Hospital and Institute | 142 | 2026-12-01 | 2026-10-09 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 298 | 2026-12-01 | 2026-10-27 |
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 214 | 2026-12-01 | 2026-10-29 |
| Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital Advanced radiotherapy techniques - Malignant Tumor, Benign Neoplasm | Not yet recruiting | IRCCS San Raffaele | 10000 | 2026-11-15 | 2026-10-29 | |
| Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab - Head and Neck Cancer | Phase 2 | Not yet recruiting | Kevin Contrera | 140 | 2026-11-15 | 2026-11-12 |
| Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer Biospecimen Collection, Carboplatin, Chemotherapy - Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Mayo Clinic | 50 | 2026-11-01 | 2026-11-09 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-11-03 |
| Role of Postoperative Radiotherapy in T1-T2N0M0 Glottic Carcinoma Involving the Anterior Commissure intensity modulated radiotherapy (IMRT) - Early Stage Glottic Squamous Cell Carcinoma Involving the Anterior Commissure | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2026-09-16 | 2026-08-24 |
| Role of Radiotherapy in T1-T2N0M0 Glottic Carcinoma With Poor Differentiation Radiation: intensity modulated radiotherapy (IMRT) - Early Stage Glottic Squamous Cell Carcinoma With Poor Differentiation | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2026-09-16 | 2026-08-24 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-09-08 | 2026-11-09 |
| Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2) - HPV-unrelated Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 104 | 2026-09-01 | 2026-08-20 |
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
Showing 20 of 594. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (82) · Head and Neck Neoplasms (75) · Nasopharyngeal Carcinoma (62) · Prostatic Neoplasms (51) · Oropharyngeal Neoplasms (30) · Carcinoma, Non-Small-Cell Lung (27) · Carcinoma, Squamous Cell (24) · Breast Neoplasms (23) · Rectal Neoplasms (23) · Glioblastoma (22) · Carcinoma (18) · Uterine Cervical Neoplasms (18) · Brain Neoplasms (16) · Neoplasm Metastasis (16) · Nasopharyngeal Neoplasms (15)
Sun Yat-sen University (45) · National Cancer Institute (NCI) (36) · Radiation Therapy Oncology Group (21) · NRG Oncology (18) · M.D. Anderson Cancer Center (17) · City of Hope Medical Center (16) · Memorial Sloan Kettering Cancer Center (16) · Mayo Clinic (11) · University of Texas Southwestern Medical Center (10) · Washington University School of Medicine (10) · Chinese Academy of Medical Sciences (9) · Fudan University (9) · UNC Lineberger Comprehensive Cancer Center (8) · AHS Cancer Control Alberta (7) · University of Washington (7)
United States (327) · China (130) · Canada (71) · France (18) · Belgium (12) · Italy (12) · Switzerland (12) · Australia (10) · India (10) · Israel (10) · United Kingdom (10) · Hong Kong (9) · South Korea (9) · Germany (8) · Japan (8)
Jun Ma, M.D. (6) · Douglas Adkins, M.D. (3) · Fang-Yun Xie, M.D. (3) · Guopei Luo, MD (3) · Guopei Zhu, M.D. (3) · Ming-Yuan Chen, MD,PhD (3) · Robert Haddad, MD (3) · Rufus Scrimger, MD (3) · Steven H Lin (3) · Wei Jiang, Ph.D. (3) · Wilson Roa, MD (3) · Anna Pawlowska (2) · Anuja Jhingran, MD (2) · Chong Zhao, MD PhD (2)
PMID 25057165, PMID 27840089, PMID 31150573, PMID 36884035, PMID 36990609, PMID 16467544, PMID 22543211, PMID 27044935, PMID 28267695, PMID 28356973, PMID 28837405, PMID 29584545, PMID 30207593, PMID 32017652, PMID 35355438, PMID 37751207, PMID 38050737, PMID 41343184, PMID 10974628, PMID 11208820, PMID 11448365, PMID 11704310, PMID 12007937, PMID 12117328, PMID 12128137, PMID 12838028, PMID 14645636, PMID 14759776, PMID 14801776, PMID 14967461, PMID 15142632, PMID 15183474, PMID 15800321, PMID 1584260, PMID 16425991, PMID 16515704, PMID 17234359, PMID 17706308, PMID 17825932, PMID 17848281, PMID 17960013, PMID 18285602, PMID 18374511, PMID 18786783, PMID 18855050, PMID 19056184, PMID 19342953, PMID 19363712, PMID 19405086, PMID 19564532
U10CA180868 (34), U10CA021661 (12), P30CA033572 (9), U10CA180820 (9), P30CA013330 (5), P30CA015083 (4), U10CA180886 (4), P30CA015704 (3), P30CA016059 (3), P30CA072720 (3), P30CA138292 (3), U10CA027469 (3), U10CA098543 (3), U19CA021239 (3), UG1CA189867 (3)